Praxis Precision Medicines, Inc. Common Stock PRAX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-05T22:21:07.069Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-05T21:48:30.050397868Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-05T22:21:05.085600+00:00
Praxis Precision Medicines, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 340.56 | 135.2% | 33.7% | 220.41 | 113.1% | 18.1% |
| 25Δ | 327.85 | 139.2% | 29.8% | 229.29 | 111.8% | 15.6% |
| 30Δ | 315.81 | 142.0% | 26.2% | 237.19 | 111.8% | 13.7% |
| 35Δ | 301.07 | 136.5% | 21.4% | 244.80 | 111.9% | 12.0% |
| 40Δ | 289.52 | 134.1% | 18.0% | 252.32 | 112.6% | 10.5% |
| 45Δ | 279.16 | 131.9% | 15.2% | 259.83 | 114.5% | 9.2% |
| 50Δ | 269.60 | 130.0% | 12.7% | 267.38 | 113.3% | 7.8% |
| 55Δ | 261.00 | 132.4% | 11.0% | 275.42 | 113.9% | 6.7% |
| 60Δ | 252.23 | 131.5% | 9.1% | 283.75 | 114.3% | 5.7% |
| 65Δ | 243.41 | 132.2% | 7.5% | 292.45 | 113.9% | 4.6% |
| 70Δ | 234.46 | 132.6% | 6.1% | 302.20 | 114.4% | 3.8% |
| 75Δ | 225.26 | 132.0% | 4.8% | 312.43 | 113.5% | 2.9% |
| 80Δ | 214.53 | 135.2% | 3.6% | 324.95 | 113.8% | 2.1% |
20Δ
- Pseudo strike
- 340.56
- IV
- 135.2%
- B/E move
- 33.7%
- Pseudo strike
- 220.41
- IV
- 113.1%
- B/E move
- 18.1%
25Δ
- Pseudo strike
- 327.85
- IV
- 139.2%
- B/E move
- 29.8%
- Pseudo strike
- 229.29
- IV
- 111.8%
- B/E move
- 15.6%
30Δ
- Pseudo strike
- 315.81
- IV
- 142.0%
- B/E move
- 26.2%
- Pseudo strike
- 237.19
- IV
- 111.8%
- B/E move
- 13.7%
35Δ
- Pseudo strike
- 301.07
- IV
- 136.5%
- B/E move
- 21.4%
- Pseudo strike
- 244.80
- IV
- 111.9%
- B/E move
- 12.0%
40Δ
- Pseudo strike
- 289.52
- IV
- 134.1%
- B/E move
- 18.0%
- Pseudo strike
- 252.32
- IV
- 112.6%
- B/E move
- 10.5%
45Δ
- Pseudo strike
- 279.16
- IV
- 131.9%
- B/E move
- 15.2%
- Pseudo strike
- 259.83
- IV
- 114.5%
- B/E move
- 9.2%
50Δ
- Pseudo strike
- 269.60
- IV
- 130.0%
- B/E move
- 12.7%
- Pseudo strike
- 267.38
- IV
- 113.3%
- B/E move
- 7.8%
55Δ
- Pseudo strike
- 261.00
- IV
- 132.4%
- B/E move
- 11.0%
- Pseudo strike
- 275.42
- IV
- 113.9%
- B/E move
- 6.7%
60Δ
- Pseudo strike
- 252.23
- IV
- 131.5%
- B/E move
- 9.1%
- Pseudo strike
- 283.75
- IV
- 114.3%
- B/E move
- 5.7%
65Δ
- Pseudo strike
- 243.41
- IV
- 132.2%
- B/E move
- 7.5%
- Pseudo strike
- 292.45
- IV
- 113.9%
- B/E move
- 4.6%
70Δ
- Pseudo strike
- 234.46
- IV
- 132.6%
- B/E move
- 6.1%
- Pseudo strike
- 302.20
- IV
- 114.4%
- B/E move
- 3.8%
75Δ
- Pseudo strike
- 225.26
- IV
- 132.0%
- B/E move
- 4.8%
- Pseudo strike
- 312.43
- IV
- 113.5%
- B/E move
- 2.9%
80Δ
- Pseudo strike
- 214.53
- IV
- 135.2%
- B/E move
- 3.6%
- Pseudo strike
- 324.95
- IV
- 113.8%
- B/E move
- 2.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 88.97% | |
| 91.22% | |
| 90.65% | |
| 91.39% | |
| 92.32% | |
| 94.63% | |
| 94.60% | |
| 95.30% | |
| 94.70% | |
| 96.53% |
Biotechnology
PRLD
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key…
More →PRME
Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology, which enables precise DNA…
More →PROK
Description unavailable
More →PRQR
ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. The company is…
More →PRTA
Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The…
More →PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is…
More →